Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma

Yu,Ying; Zhao,Xiaosu; Zhang,Yu; Kang,Yanling; Wang,Jiaqi; Liu,Yingchun

doi:10.3892/or.2015.3947

Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma

Authors:
- Ying Yu
- Xiaosu Zhao
- Yu Zhang
- Yanling Kang
- Jiaqi Wang
- Yingchun Liu
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, The Nursing Department of the First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pediatric Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 5, 2015 https://doi.org/10.3892/or.2015.3947
Pages: 407-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (CDDP) is a chemotherapeutic drug that is often used for the treatment of hepatoblastoma. However, many patients acquire resistance to therapeutic agents leading to local and distant treatment failure. It has been shown that suppression survivin contributed to the inhibition of tumor growth and enhanced chemotherapeutic sensitivity in several types of cancer. The aim of the present study was to determine whether treatment with sepantronium bromide (YM155), a novel small molecule inhibitor of survivin, enhanced the sensitivity of CDDP to hepatoblastoma cells, leading to the therapeutic efficacy of cisplatin. In vitro and in vivo models were used to examine the anticancer efficacy of YM155, either as a monotherapy or in combination with CDDP to identify more effective therapeutics against hepatoblastoma. The results showed that survivin expression was upregulated in hepatoblastoma tissues and cell lines, and that YM155 inhibited survivin expression in hepatoblastoma cells in a dose-dependent manner. YM155 enhanced sensitivity of CDDP to human HepG2 and HuH-6 hepatoblastoma cells. The YM155 combination with CDDP in hepatoblastoma cells significantly decreased cell proliferation and formation, and induced cell apoptosis than either agent alone. In a mouse xenograft model, YM155 combined with CDDP significantly suppressed tumor growth compared to the monotherapy. Taken together, these findings suggested that the combination of YM155 and CDDP is a promising drug candidate for the treatment of hepatoblastoma.

View Figures

View References

1	Stocker JT: Hepatoblastoma. Semin Diagn Pathol. 11:136–143. 1994.PubMed/NCBI
2	Schoofs G, Braeye L, Vanheste R, Verswijvel G, Debiec-Rychter M and Sciot R: Hepatic rhabdomyosarcoma in an adult: A rare primary malignant liver tumor. Case report and literature review. Acta Gastroenterol Belg. 74:576–581. 2011.
3	Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH and Meyers RL: Hepatoblastoma state of the art: Pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 26:19–28. 2014. View Article : Google Scholar
4	Davies JQ, de la Hall PM, Kaschula RO, Sinclair-Smith CC, Hartley P, Rode H and Millar AJ: Hepatoblastoma - evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases. J Pediatr Surg. 39:1321–1327. 2004. View Article : Google Scholar : PubMed/NCBI
5	Zhang YT, Feng LH, Zhong XD, Wang LZ and Chang J: Single-agent cisplatin treatment of children with high-risk hepatoblastoma. J Pediatr Hematol Oncol. 36:271–275. 2014. View Article : Google Scholar
6	Qayed M and Katzenstein HM: Dose-intensive cisplatin for hepatoblastoma: Have you heard? Lancet Oncol. 14:791–792. 2013. View Article : Google Scholar : PubMed/NCBI
7	Colnaghi R, Connell CM, Barrett RM and Wheatley SP: Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem. 281:33450–33456. 2006. View Article : Google Scholar : PubMed/NCBI
8	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
9	Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM and Ryan BM: Survivin: A promising tumor biomarker. Cancer Lett. 249:49–60. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
11	Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, et al: Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol. 37:89–96. 2010.PubMed/NCBI
12	Chandele A, Prasad V, Jagtap JC, Shukla R and Shastry PR: Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 6:29–40. 2004. View Article : Google Scholar : PubMed/NCBI
13	Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, et al: Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 66:4263–4272. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kunze D, Erdmann K, Froehner M, Wirth MP and Fuessel S: siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res. 32:4313–4318. 2012.PubMed/NCBI
16	Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S and Manome Y: Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 65:10–19. 2005. View Article : Google Scholar : PubMed/NCBI
17	Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kawano H, Shakushiro K, Nakata M, Kita A, Maeda A, Watanabe S, Sako K and Oku N: Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant. Eur J Pharm Biopharm. 88:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
19	Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M, et al: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
20	Minematsu T, Iwai M, Sugimoto K, Shirai N, Nakahara T, Usui T and Kamimura H: Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos. 37:619–628. 2009. View Article : Google Scholar
21	Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M: Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res. 35:787–792. 2011. View Article : Google Scholar : PubMed/NCBI
22	Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 23:968–973. 2012. View Article : Google Scholar
23	Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and Shamsili S: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 27:4481–4486. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R: A multicenter phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 29:161–166. 2011. View Article : Google Scholar
25	Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, Arradaza N, Teknos TN and Kumar P: YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther. 11:1988–1998. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhang K, Li Y, Liu W, Gao X and Zhang K: Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo. Mol Med Rep. 11:639–644. 2015.
27	Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, et al: Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull. 28:565–568. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kappler M, Köhler T, Kampf C, Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C, Rieber EP, Schmidt H, et al: Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer. 95:360–363. 2001. View Article : Google Scholar : PubMed/NCBI
29	Uehara S, Oue T, Kawatsu M, Nara K and Fukuzawa M: Increased expression of survivin in hepatoblastoma after chemotherapy. Eur J Pediatr Surg. 23:400–404. 2013. View Article : Google Scholar : PubMed/NCBI
30	Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI
31	Ryan BM, O’Donovan N and Duffy MJ: Survivin: A new target for anti-cancer therapy. Cancer Treat Rev. 35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
32	Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H, et al: YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs. 22:454–462. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kaneko N, Mitsuoka K, Amino N, Yamanaka K, Kita A, Mori M, Miyoshi S and Kuromitsu S: Combination of YM155, a survivin suppressant, with bendamustine and rituximab: A new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma. Clin Cancer Res. 20:1814–1822. 2014. View Article : Google Scholar : PubMed/NCBI
34	Liang H, Zhang L, Xu R and Ju XL: Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol Sci. 17:2909–2915. 2013.PubMed/NCBI
35	Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI
36	Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N and Sasamata M: Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res. 17:5423–5431. 2011. View Article : Google Scholar : PubMed/NCBI
37	Graf RP, Keller N, Barbero S and Stupack D: Caspase-8 as a regulator of tumor cell motility. Curr Mol Med. 14:246–254. 2014. View Article : Google Scholar : PubMed/NCBI
38	Feng W, Yoshida A and Ueda T: YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 435:52–57. 2013. View Article : Google Scholar : PubMed/NCBI